APOGEE THERAPEUTICS INC - ZUMILOKIBART SHOWS GOOD TOLERABILITY AND SAFETY PROFILE SIMILAR TO OTHER DRUGS IN ITS CLASS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 23 2026
0mins
Should l Buy APGE?
Source: moomoo
Therapeutics Overview: The article discusses the therapeutic agent ZUMILOKIBART, highlighting its safety profile and efficacy.
Safety Profile: ZUMILOKIBART is noted to have a safety profile consistent with other agents in its class, indicating it is well-tolerated.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APGE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APGE
Wall Street analysts forecast APGE stock price to rise
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 77.820
Low
83.00
Averages
105.67
High
137.00
Current: 77.820
Low
83.00
Averages
105.67
High
137.00
About APGE
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of XBI ETF's 52-Week Price Fluctuations
- Price Range Analysis: The XBI ETF's 52-week low is $66.66 per share, with a high of $132.09, and a recent trading price of $119.75, indicating stability within its volatility range that may attract investor interest.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average can provide valuable insights for investors, aiding in market trend assessment and timing of investments.
- ETF Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on significant inflows (new units created) or outflows (old units destroyed), which will affect the underlying holdings of the ETF and influence market dynamics.
See More
Apogee Therapeutics CEO Sells 20,000 Shares of Stock
- Executive Stock Sale: Apogee Therapeutics CEO Michael Henderson sold 20,000 shares of common stock on March 11, 2026, for a total value of $1.5 million, retaining approximately 1.15 million shares valued at around $86.11 million post-transaction, indicating confidence in the company's future prospects.
- Transaction Scale Analysis: The sale of 20,000 shares aligns with Henderson's recent average sale size, representing 1.71% of his direct holdings, consistent with his historical trading pattern, which reflects stability and consistency in the market.
- Company Financial Status: Apogee Therapeutics has a current market capitalization of $5.5 billion, and despite a trailing twelve-month net income of -$255.84 million, its stock price has surged by 98% over the past year, demonstrating strong market confidence in its biologic therapeutic products.
- Future Development Outlook: The company recently completed a $350 million equity offering expected to close on Thursday, which will strengthen its financial position and support ongoing clinical development, particularly in the upcoming Phase 3 trials, making it crucial for investors to focus on the forthcoming positive data releases.
See More
Apogee Therapeutics Prices Public Offering at $70 per Share
- Offering Size: Apogee Therapeutics has announced a public offering of 5,000,000 shares at a price of $70.00 per share, with expected gross proceeds of approximately $350 million, which will significantly bolster the company's funding for R&D and market expansion.
- Underwriter Arrangement: The offering is managed by Jefferies, TD Cowen, Stifel, and Guggenheim Securities, reflecting strong market confidence in Apogee and potentially enhancing its reputation within the biotechnology sector.
- Additional Share Option: Apogee has granted underwriters a 30-day option to purchase an additional 750,000 shares, providing flexibility that may further enhance the company's capital-raising capabilities to meet future market demands.
- Market Outlook: With a focus on treating major immunological diseases like atopic dermatitis, Apogee's innovative biologics are expected to attract increased investor interest, thereby boosting the company's competitiveness in the rapidly growing biotechnology market.
See More
Apogee Therapeutics Prices Upsized Public Offering of 5M Shares
- Upsized Offering: Apogee Therapeutics has announced an upsized public offering of 5 million shares at $70.00 per share, with total gross proceeds expected to reach approximately $350 million, reflecting strong market demand compared to the previously announced $300 million target.
- Underwriter Option: The offering includes an option for underwriters to purchase up to 750,000 additional shares within 30 days at the same price, enhancing the company's financial flexibility and potential capital raise capabilities.
- Closing Timeline: The offering is set to close on March 26, 2026, marking a proactive approach by Apogee in the capital markets to secure funding for future research and market expansion initiatives.
- Positive Market Reaction: Following the announcement of the offering, Apogee Therapeutics' stock price rose due to positive developments in its eczema treatment, indicating investor confidence in the company's future potential.
See More
Apogee Therapeutics Successfully Prices Public Offering
- Offering Size: Apogee Therapeutics announced the pricing of 5,000,000 shares at $70.00 each, expecting gross proceeds of approximately $350 million, which will significantly support the company's R&D and market expansion efforts.
- Underwriter Arrangement: Jefferies, TD Cowen, Stifel, and Guggenheim Securities are acting as joint book-running managers for the offering, ensuring professional management and market credibility, thereby enhancing investor confidence.
- Additional Share Option: Apogee granted underwriters a 30-day option to purchase an additional 750,000 shares, a flexible arrangement that could further increase total proceeds and enhance the company's financial flexibility.
- Market Outlook: The successful offering provides funding for Apogee's innovative biologics targeting conditions like atopic dermatitis and asthma, expected to boost its competitiveness in the inflammatory and immunology markets, helping the company achieve best-in-class efficacy and dosing objectives.
See More
Apogee Therapeutics Launches $300 Million Public Offering
- Funding Size: Apogee Therapeutics has announced a public offering of $300 million in common stock, which is intended to fund clinical trials and commercial readiness activities for its antibody programs, thereby enhancing its competitive edge in the biopharmaceutical sector.
- Stock Price Reaction: Following the announcement, APGE's stock rose by 2.04% to $80.86, reflecting market confidence in the company's future, especially after the positive clinical data release for its lead drug.
- Underwriter Arrangement: Apogee plans to grant underwriters a 30-day option to purchase up to an additional $45 million in common stock, a strategy that will provide the company with greater financial flexibility to support its R&D efforts.
- Clinical Progress: The company's lead candidate, Zumilokibart, has shown positive 52-week Phase 2 data for atopic dermatitis, further solidifying its market position in treating inflammatory and immunological diseases.
See More
Analysis of XBI ETF's 52-Week Price Fluctuations
- Price Range Analysis: The XBI ETF's 52-week low is $66.66 per share, with a high of $132.09, and a recent trading price of $119.75, indicating stability within its volatility range that may attract investor interest.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average can provide valuable insights for investors, aiding in market trend assessment and timing of investments.
- ETF Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on significant inflows (new units created) or outflows (old units destroyed), which will affect the underlying holdings of the ETF and influence market dynamics.
See More
Apogee Therapeutics CEO Sells 20,000 Shares of Stock
- Executive Stock Sale: Apogee Therapeutics CEO Michael Henderson sold 20,000 shares of common stock on March 11, 2026, for a total value of $1.5 million, retaining approximately 1.15 million shares valued at around $86.11 million post-transaction, indicating confidence in the company's future prospects.
- Transaction Scale Analysis: The sale of 20,000 shares aligns with Henderson's recent average sale size, representing 1.71% of his direct holdings, consistent with his historical trading pattern, which reflects stability and consistency in the market.
- Company Financial Status: Apogee Therapeutics has a current market capitalization of $5.5 billion, and despite a trailing twelve-month net income of -$255.84 million, its stock price has surged by 98% over the past year, demonstrating strong market confidence in its biologic therapeutic products.
- Future Development Outlook: The company recently completed a $350 million equity offering expected to close on Thursday, which will strengthen its financial position and support ongoing clinical development, particularly in the upcoming Phase 3 trials, making it crucial for investors to focus on the forthcoming positive data releases.
See More
Apogee Therapeutics Prices Public Offering at $70 per Share
- Offering Size: Apogee Therapeutics has announced a public offering of 5,000,000 shares at a price of $70.00 per share, with expected gross proceeds of approximately $350 million, which will significantly bolster the company's funding for R&D and market expansion.
- Underwriter Arrangement: The offering is managed by Jefferies, TD Cowen, Stifel, and Guggenheim Securities, reflecting strong market confidence in Apogee and potentially enhancing its reputation within the biotechnology sector.
- Additional Share Option: Apogee has granted underwriters a 30-day option to purchase an additional 750,000 shares, providing flexibility that may further enhance the company's capital-raising capabilities to meet future market demands.
- Market Outlook: With a focus on treating major immunological diseases like atopic dermatitis, Apogee's innovative biologics are expected to attract increased investor interest, thereby boosting the company's competitiveness in the rapidly growing biotechnology market.
See More
Apogee Therapeutics Prices Upsized Public Offering of 5M Shares
- Upsized Offering: Apogee Therapeutics has announced an upsized public offering of 5 million shares at $70.00 per share, with total gross proceeds expected to reach approximately $350 million, reflecting strong market demand compared to the previously announced $300 million target.
- Underwriter Option: The offering includes an option for underwriters to purchase up to 750,000 additional shares within 30 days at the same price, enhancing the company's financial flexibility and potential capital raise capabilities.
- Closing Timeline: The offering is set to close on March 26, 2026, marking a proactive approach by Apogee in the capital markets to secure funding for future research and market expansion initiatives.
- Positive Market Reaction: Following the announcement of the offering, Apogee Therapeutics' stock price rose due to positive developments in its eczema treatment, indicating investor confidence in the company's future potential.
See More
Apogee Therapeutics Successfully Prices Public Offering
- Offering Size: Apogee Therapeutics announced the pricing of 5,000,000 shares at $70.00 each, expecting gross proceeds of approximately $350 million, which will significantly support the company's R&D and market expansion efforts.
- Underwriter Arrangement: Jefferies, TD Cowen, Stifel, and Guggenheim Securities are acting as joint book-running managers for the offering, ensuring professional management and market credibility, thereby enhancing investor confidence.
- Additional Share Option: Apogee granted underwriters a 30-day option to purchase an additional 750,000 shares, a flexible arrangement that could further increase total proceeds and enhance the company's financial flexibility.
- Market Outlook: The successful offering provides funding for Apogee's innovative biologics targeting conditions like atopic dermatitis and asthma, expected to boost its competitiveness in the inflammatory and immunology markets, helping the company achieve best-in-class efficacy and dosing objectives.
See More
Apogee Therapeutics Launches $300 Million Public Offering
- Funding Size: Apogee Therapeutics has announced a public offering of $300 million in common stock, which is intended to fund clinical trials and commercial readiness activities for its antibody programs, thereby enhancing its competitive edge in the biopharmaceutical sector.
- Stock Price Reaction: Following the announcement, APGE's stock rose by 2.04% to $80.86, reflecting market confidence in the company's future, especially after the positive clinical data release for its lead drug.
- Underwriter Arrangement: Apogee plans to grant underwriters a 30-day option to purchase up to an additional $45 million in common stock, a strategy that will provide the company with greater financial flexibility to support its R&D efforts.
- Clinical Progress: The company's lead candidate, Zumilokibart, has shown positive 52-week Phase 2 data for atopic dermatitis, further solidifying its market position in treating inflammatory and immunological diseases.
See More
